Regeneron Pharmaceuticals (($REGN)) announced an update on their ongoing clinical study. Regeneron Pharmaceuticals is conducting a Phase 3 ...

The U.S. Court of Appeals for the First Circuit, in United States v. Regeneron, has joined the Sixth and Eighth Circuits in ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the most profitable biotech stocks to invest in now. Canaccord ...

Following the FDA approval of linvoseltamab (Lynozyfic; Regeneron) for heavily pretreated multiple myeloma, Sundar Jagannath, MBBS, highlights its potential for earlier use, increased accessibility, ...

Novo Nordisk ( NVO 1.34%) and Regeneron Pharmaceuticals ( REGN -0.27%), two leading drugmakers, have underperformed for most ...

Wall Street analysts forecast that Regeneron (REGN) will report quarterly earnings of $8.03 per share in its upcoming release, pointing to a year-over-year decline of 30.5%. It is anticipated that ...

Regeneron Pharmaceuticals will release its second-quarter earnings next month, and analysts anticipate a double-digit profit ...

Over 100 prominent companies are currently engaged in developing treatments for osteoarthritis. Among them, Biosplice Therapeutics has drug candidates that have reached the most advanced stage—Phase ...

Regeneron saw its sales rise in recent years, led by its Covid-19 multi-antibody therapy, which garnered $6 billion in 2021 sales. However, with the pandemic now behind us, sales declined in 2022.

Regeneron Pharmaceuticals Inc said on Monday a single dose of its antibody cocktail reduced the risk of contracting COVID-19 by 81.6% in a late-stage trial, in the two to eight months period ...

Regeneron Pharmaceuticals Inc. REGN -0.01% suspended testing of its Covid-19 antibody drug in the sickest hospitalized patients because of a safety concern, the latest setback for antibody-drug ...

Regeneron Pharmaceuticals Inc on Wednesday failed to persuade a federal judge in New York to throw out a lawsuit over its alleged misuse of a patented protein to test its breakthrough COVID-19 ...